Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | TP53 | P04637 | 5/20 | 0.46 |
| ▸ | PRNP | P04156 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1083101 | 0.86 | ACKR3 (0.61) | ACKR3SMN1; SMN2RXFP1MAPTTP53 | |
| SCHEMBL1550468 | 0.86 | ACKR3 (0.72) | ACKR3SMN1; SMN2RXFP1MAPTTP53 | |
| SCHEMBL1072088 | 0.86 | ACKR3 (0.57) | ACKR3SMN1; SMN2RXFP1MAPTTP53 | |
| SCHEMBL1023539 | 0.85 | ACKR3 (0.75) | ACKR3SMN1; SMN2MAPTTP53POLB | |
| SCHEMBL1073965 | 0.84 | ACKR3 (0.54) | ACKR3SMN1; SMN2RXFP1MAPTTP53 | |
| SCHEMBL1022303 | 0.81 | ACKR3 (0.62) | ACKR3SMN1; SMN2MAPTTP53POLB | |
| SCHEMBL1073045 | 0.80 | ACKR3 (0.54) | ACKR3SMN1; SMN2MAPTTP53POLB | |
| SCHEMBL13762930 | 0.80 | ACKR3 (0.60) | ACKR3SMN1; SMN2MAPTTP53POLB | |
| SCHEMBL13762943 | 0.77 | ACKR3 (0.69) | ACKR3SMN1; SMN2RXFP1MAPTTP53 | |
| SCHEMBL1074524 | 0.77 | SMN1; SMN2 (0.67) | SMN1; SMN2RXFP1MAPTTP53PRNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2314590-A1 | Substituted quinolones and methods of use | ChemoCentryx, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-2314590-A1 | Substituted quinolones and methods of use | ChemoCentryx, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-1954274-B8 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-1954274-B1 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2010-11-03 | — | — | EP | disclosed |
| US-7557213-B2 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557213-B2 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557213-B2 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1954274-A4 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1954274-A2 | SUBSTITUTED QUINOLONES AND METHODS OF USE | ChemoCentryx Inc (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20070167443-A1 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2007-07-19 | — | — | US | disclosed |
| US-20070167443-A1 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2007-07-19 | — | — | US | disclosed |
| US-20070167443-A1 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2007-07-19 | — | — | US | disclosed |
| WO-2007059108-A2 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007059108-A2 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167443-A1 | Substituted quinolones and methods of use | TOP2A, NQO2, TOP2B | ACKR3 3624/4885SMN1; SMN2 2712/4885RXFP1 4610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.